Rationale: Early vascular changes in metabolic disease that precipitate the development of cardiovascular complications are largely driven by reactive oxygen species accumulation, yet the extent to which excess reactive oxygen species derive from specific NADPH oxidase isoforms remains ill defined.
O verproduction of reactive oxygen species (ROS) is a key mechanism by which insulin resistance, obesity, and other components of the metabolic syndrome (MetS) lead to the development of vascular disease. 1, 2 For this reason, restoring redox balance has long been hailed as a promising therapeutic strategy; however, scavenging of ROS with antioxidants has proven ineffective for the prevention of cardiovascular death in the majority of large randomized clinical trials. 3, 4 Several factors may account for this unexpected failure of antioxidants, including the indiscriminate scavenging of ROS, which have both physiological and pathophysiological roles. Specific targeting of pathophysiological ROS may offer a more efficacious approach; however, this will depend on a better understanding of the source of ROS under conditions of metabolic disease.
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Members of the NADPH oxidase (Nox) family of enzymes function to generate physiological levels of ROS, but under various pathological conditions are significant contributors to the surplus of ROS characteristic of oxidative stress. 5 Excess ROS exert deleterious effects on the vasculature through a variety of mechanisms. One such mechanism is the quenching of NO by superoxide (O 2 − ) and consequent blunting of endothelium-mediated vasodilation. Loss of endothelial function in the microvasculature is a significant predictor of end-organ damage and cardiovascular mortality in metabolically compromised patients. [6] [7] [8] Although Nox enzymes have been implicated in the pathogenesis of metabolic disease by a handful of studies, relative contributions of the different Nox isoforms in animal models of vascular disease have not been sufficiently delineated because the majority of studies use pharmacological agents that lack isoform specificity, and conflicting results defer definitive conclusions. 9, 10 Further, there is currently a lack of data with respect to the role of specific Nox isoforms in microvascular changes because investigation to date has focused primarily on the macrovascular complications of metabolic disease. Four isoforms of Nox enzymes are present in the vasculature: Nox1, 2, 4, and 5. The absence of Nox5 from rodent genomes precludes study of its functional role. Constitutively active Nox4 preferentially generates H 2 O 2 and does not disrupt NO signaling, whereas Nox1 and 2 are the primary enzymes responsible for inducible O 2 − formation. 11 Nox2 is expressed in phagocytes and heavily involved in host defenses, and loss of Nox1 substantially reduces survival rates in diabetic mice. 12 Nox1, expressed in endothelial cells and vascular smooth muscle cells, 11 may be a key driver of oxidative stress within an aberrant metabolic state given that its activity in vitro is induced in the presence of high glucose or saturated fatty acids. [12] [13] [14] [15] Indeed, our laboratory previously demonstrated that restoring glycemic control via deletion of PTP1B or myostatin improved microvascular function and attenuated Nox1 expression. 16 These findings suggest that the metabolic milieu of obesity is transduced to the vasculature through Nox1.
Along with the metabolic derangements that together constitute MetS, the leptin receptor deficient (db/db) mouse presents with endothelial dysfunction of the microvasculature. This microvascular dysfunction in the db/db mouse is accompanied by increased Nox1 expression and ameliorated after ex vivo incubation with GKT136901-a Nox1/4 inhibitor-as demonstrated previously by our group. 16 Herein, a model whereby Nox1 is selectively deleted in the db/db mouse was developed to definitively determine the role of Nox1 in metabolic microvascular disease. Several indices of vascular function were measured ex vivo in mesenteric resistance arteries, and extensive metabolic profiling was performed, providing the first comprehensive investigation into the role of Nox1 in microvascular disease under conditions of metabolic dysfunction. ). At ≈12 weeks of age, whole-body composition of fat and lean mass was determined by nuclear magnetic resonance, and intraperitoneal glucose tolerance tests were performed to examine glucose homeostasis. A subset of mice were monitored for 4 days with a comprehensive laboratory animal monitoring system for noninvasive measurement of energy expenditure, locomotor activity, and food intake. At sacrifice, animals were anesthetized in an induction chamber and subsequently decapitated with a guillotine. Plasma was isolated and later analyzed for fasting insulin and lipid levels. A subset of lean HW and HK mice were treated with low-dose streptozotocin (50 mg/kg) for 5 consecutive days and euthanized 5 weeks post-treatment after confirmation of hyperglycemia.
Methods

Animal Model and Metabolic Profiling
Ex Vivo Vascular Function
In ice-cold Krebs solution, 2nd order (≈150 µm internal diameter) mesenteric arteries were isolated and mounted in a small vessel myograph. After equilibration, cumulative concentration-response curves were generated in preconstricted vessels by adding increasing concentrations of acetylcholine and sodium nitroprusside. In some experiments, vessels were preincubated with L-NG-nitroarginine methyl ester (L-NAME) or Tempol for 30 minutes before vasodilator was added. Contractile responses to increasing doses of phenylephrine were also measured in some vessels. Myogenic tone was determined by measuring the active diameter in the presence of Ca 2+ and passive diameter in the absence of Ca 2+ , at 20 mm Hg increments.
Oxidative Stress
Cross-sections of mesenteric arteries were embedded in optimal cutting tissue compound (Tissue-Tek) and slow frozen while suspended in isopentane cooled to −80°C. 
Novelty and Significance
What Is Known?
• ROS are key pathogenic factors in metabolic disease.
• Nox is expressed in the vasculature and produces ROS.
• In an in vitro setting, glucose and other metabolic stimuli induce Nox1 activity.
What New Information Does This Article Contribute?
• Nox1 contributes importantly to oxidant load in an in vivo setting of metabolic disease.
• Nox1-derived ROS play a critical role in the development of microvascular dysfunction in metabolic disease.
• Inhibition of Nox1 may be an effective therapeutic strategy in the prevention of vascular complications.
Although ROS have been implicated in the pathogenesis of metabolic disease and its sequelae, clinically tested approaches to mitigating ROS have proven ineffective in preventing cardiovascular complications. Directly targeting enzymatic sources of ROS represents a potential alternative strategy that has not been sufficiently tested in animal models of metabolic disease. We found that loss of Nox1 through genetic deletion reduced oxidant load and prevented the loss of myogenic tone and NO-mediated microvascular dilation in the db/db (leptin receptor deficient) model, without impacting the degree of metabolic dysfunction. These findings link Nox1 to microvascular dysfunction in an in vivo setting of metabolic disease, and implicate oxidative stress in the autoregulatory dysfunction that occurs in abnormal metabolic states.
at room temperature for 30 minutes in a covered humidity chamber. Replacement of the primary antibody with PBS was used as negative control. Nuclei were stained with Sytox Green (Life Technologies). A second experiment was performed wherein freshly isolated vessels were incubated with dihydroethidium, subsequently washed and slow frozen in optimal cutting tissue compound (Tissue-Tek). A subset of vessels was simultaneously treated with superoxide dismutase (SOD) polyethylene glycol (PEG-SOD), to confirm the specificity of dihydroethidium to superoxide. All images were captured on a Zeiss LSM780 confocal microscope at ×40 magnification and analyzed with ImageJ. Additionally, plasma levels of thiobarbituric acid-reactive substances-a by-product of lipid peroxidation-was measured using a colorimetric assay according to the manufacturer's instructions (Cayman Chemicals, Ann Arbor, MI).
Expression of Nox and Its Subunit P22 phox
For determination of gene or protein expression, vessels were pooled from 3 to 5 animals for each sample included in the analysis. Complementary DNA synthesized from isolated RNA was analyzed for the following genes using polymerase chain reaction: Nox1, Nox4, P22 phox , and endothelial NO synthase (eNOS). For quantitative polymerase chain reaction, the expression of individual target genes is reported as fold change relative to the control group using the 2 −ΔΔct method, with RPL7 (ribosomal protein L7) as the housekeeping gene. Primers used for analysis are shown in Online Table I and a representative blot is shown in Online Figure I . The phosphorylation status of eNOS was determined by Western blot. Briefly, extracted protein was separated by gel electrophoresis and transferred to polyvinylidene difluoride membranes. Membranes were blocked and incubated overnight with antibodies against phospho-eNOS and total eNOS (Cell Signaling Technology, Danvers, MA).
Results
Nox1 Deletion Does Not Impact the Degree of Obesity in db/db Mice
Metabolic profiling of the 4 mouse genotypes was performed to determine the impact of Nox1 deletion on metabolic function. At 12 weeks of age, body weight in the KW and KK groups was 68% (P<0.001) and 57% (P<0.001) higher than lean HW and HK animals, respectively (Table 1) . Nuclear magnetic resonance spectroscopy determined that whole-body percentage fat was 270% higher in KW versus HW (P<0.001) and 250% higher in KK versus HK (P<0.001) groups (Online Figure II) . In obese mice, absolute fat mass (%×body weight) was 34±3.1 g in KW versus 5±0.8 g in HW (P<0.001) and 24±2.7 g in KK versus 5±0.5 g in HK (P<0.001). Whole-body percentage lean mass was 60% (P<0.001) and 50% (P<0.001) lower in KW and KK mice compared with their respective controls (Online Figure II) . Absolute lean mass (%×body weight) was 12±0.9 g in KW versus 18±0.5 g in HW (P<0.001) and 15±0.8 g in KK versus 18±0.4 g in HK (P<0.05). No differences in body weight or composition were present in obese KW versus KK or lean HW versus HK.
Blood Glucose and Lipid Control Are Similarly Compromised in db/db Mice With and Without Nox1 Deletion
Indices of glycemic control are shown in Online Figure II and Table 1 . Blood glucose was similarly increased in KW (386±49.1 mg/dL) and KK (385±50.9 mg/dL) mice compared with HW (205±16.8 mg/dL) and HK (184±17.0 mg/dL), respectively (both P<0.01). A similar pattern was observed for HbA1c, where both obese groups exhibited markedly higher levels (KW, 8.6±0.68%; KK, 10.1±0.97%) relative to lean controls (HW, 4.7±0.1%; HK, 4.5±1.2%). Likewise, fasting plasma insulin levels were increased in KW (1.30±0.173 ng/ mL) versus HW (0.22±0.006 ng/mL) and KK (1.53±0.073 ng/ mL) versus HK (0.06±0.006 ng/mL; both P<0.001). Glucose clearance after a glucose challenge was impaired to the same degree in obese KW and KK mice (Online Figure II) . Area under the curve was increased in KW versus HW (P<0.05) and not different between KW and KK (HW, 14 289±3104 mg·dL·min; HK, 19 718±2248 mg·dL·min; KW, 34 392±5842 mg·dL·min; KK, 31 848±2872 mg·dL·min). No differences were found when comparing the 2 lean groups or the 2 obese groups in any of the aforementioned measurements of glycemic control. Fasting plasma triglyceride, cholesterol, and nonesterified fatty acid levels are shown in Table 1 
Nox1 Deletion Does Not Influence the Degree of Energy Expenditure Reduction in db/db Mice
Food intake, locomotor activity, and energy expenditure were monitored for 4 days; data are shown in Table 1 . VO 2 and VCO 2 were reduced by 44% to 45% in KW and KK mice relative to lean controls (all P<0.001). Respiratory exchange ratio and heat production were comparable among the 4 groups. 
Microvascular Endothelial Function and NO Bioavailability Are Restored in db/db Mice With Nox1 Deletion
Microvascular function was evaluated by measuring dilatory responses of pressurized mesenteric arteries to vasoactive agents. Dilatory responses to acetylcholine in preconstricted mesenteric arteries are shown in Figure 1 . A 50% reduction in maximal dilatory responses to acetylcholine was observed in KW mice, indicating endothelial dysfunction. Maximal acetylcholine responses in KK animals were comparable with lean controls (HK). There were no differences in logEC 50 for acetylcholine responses among the 4 groups. Nox1 deletion also improved endothelium-dependent responses to acetylcholine in microvessels from lean mice made diabetic by streptozotocin treatment ( Figure 2) . Next, the mechanism by which Nox1 deletion impacts endothelium-independent vasodilation was assessed. Vessels were preincubated with L-NAME-an eNOS inhibitor-to assess the contribution of NO to endothelial dysfunction. L-NAME treatment reduced maximal dilatory responses to acetylcholine by 60% to 70% in lean HW and HK groups. L-NAME had no impact on responses in KW mice, consistent with impaired NOdependent signaling; yet reduced maximal dilation by 64% in KK animals ( Figure 3 ). The contribution of superoxide (O 2 − ) to endothelium-dependent responses was determined by preincubating the vessels with Tempol-an O 2 − dismutase mimetic. Tempol improved acetylcholine responses ≈60% in KW mice but had no effect on dilation in KK and lean controls (Figure 3 ).
Vascular Smooth Muscle Cell Function Is Rescued in db/db Mice With Nox1 Deletion
Vascular smooth muscle cell function was assessed by measuring dilatory responses to sodium nitroprusside-an NO donor-and myogenic reactivity to incremental increases in intraluminal pressure. Sodium nitroprusside responses are shown in Figure 4 . Maximal responses to sodium nitroprusside were reduced by ≈50% in mesenteric arteries from KW animals compared with HW control (P<0.0001), yet comparable between KK and HK mice. Figure 5 shows active and passive diameters at intraluminal pressures between 20 and 120 mm Hg in the 4 groups. In lean animals, myogenic tone developed at 80 mm Hg, whereas tone development is both delayed and blunted in KW animals. The percentage of myogenic tone at each pressure was calculated and shown in Online Figure  III . At each pressure, the percentage of myogenic tone was decreased in the KW mice compared with HW. This impairment in myogenic reactivity seems independent of changes in vascular wall stiffness, as measured by diameter changes 
Nox1 Deletion Abolishes Oxidative Stress in the Microvasculature of db/db Mice
Nitrotyrosine is a product of ROS and reactive nitrogen species-mediated modification of tyrosine residues and has been widely used as a marker of oxidative stress. Antinitrotyrosine antibody immunoreactivity was high in mesenteric arteries from KW mice but markedly attenuated in KK arteries ( Figure 6 ). Staining in HW and HK arteries was comparable with negative control. Total oxidant load was inferred from the quantification of thiobarbituric acid-reactive substances in the plasma. There was a significantly higher circulating level of thiobarbituric acid-reactive substances in KW mice (P<0.001), which was significantly attenuated with Nox1 deletion (KW versus KK P<0.001; Figure 6 ). Superoxide production was measured in vessels stained with dihydroethidium ( Figure 7) . Dihydroethidium fluorescence was negligible in HW vessels and increased in KW. Staining for dihydroethidium in KW sections was abolished when simultaneously incubated with SOD (PEG-SOD).
Nicotinamide Adenine Dinucleotide Phosphate Oxidase Subunit (P22 phox ) Expression Is Increased and Nox4 Expression Unchanged in Mesenteric Arteries of db/db Mice
Expression of Nox1 and its subunit is shown in Figure 8 . Expression of Nox1 in the vasculature was negligible in HW, HK, and KK mice, such that there was no detectable signal in real-time polymerase chain reaction. Amplicons for Nox1 were separated on an agarose gel, showing a strong band for the KW vessels, whereas there were no detectable bands in the Nox1-null animals and in the lean controls. Real-time polymerase chain reaction revealed that the mRNA expression of P22 phox -a subunit required for the activation of Nox1, Nox2, and Nox4 isoforms of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-was increased in db/ db (P<0.05), but unchanged in KK mice, relative to control (HK, 1.32±0.23-fold change versus HW; KW, 1.72±0.20-fold change versus HW; KK, 1.44±0.19-fold change versus HW). There were no changes in the mRNA levels of Nox4 or eNOS in mesenteric arteries between the 4 groups. The ratio of phosphorylated eNOS relative to total eNOS was also unchanged between groups, as determined by Western blot.
Discussion
Despite compelling evidence implicating oxidative stress as a key mechanism underlying the vascular complications of MetS, there is yet no approved therapeutic specifically designed to temper ROS accumulation. In this regard, progress necessitates a deeper understanding of the chief sources of ROS in the setting of metabolic dysfunction and their contribution to the development of vasculopathy. The distinct role of Nox1 was examined in the present study by using a novel transgenic approach whereby Nox1 is selectively deleted in the db/db mouse. Endothelial and smooth muscle dysfunction present in the microvessels of db/db mice were rescued with Nox1 deletion, identifying Nox1 as a critical source of ROS and mediator of the early vascular changes that characterize incipient cardiovascular disease. Importantly, we performed comprehensive metabolic profiling that showed Nox1 deletion to have no impact on the degree of obesity, glucose intolerance, and dyslipidemia in db/db mice, thus, eliminating the possibility that the improvement in vascular function is because of an off-target effect of Nox1 deletion on metabolic homeostasis. Metabolic stimuli abundant under such conditions impart deleterious effects on the vasculature largely through stimulation of local ROS production, as evinced by a considerable body of in vitro data in the literature. Herein, our − generation in vessels from Dahl saltsensitive 18 and deoxycorticosterone acetate salt-induced hypertensive rats 19 after pharmacological inhibition of Nox enzymes. These studies along with in vitro 20 data and data in Nox1 smooth muscle overexpressing mice 21 demonstrate that Nox1 mediates the pressor and hypertrophic responses to angiotensin II. In contrast, there remains a scarcity of information on the contribution of Nox1 to the development of microvascular pathology in the setting of metabolic disease. To date, the majority of evidence relies heavily on in vitro data revealing Nox1 as a mediator of the cellular responses to metabolic stimuli that precipitate atherogenesis. For instance, Gray et al 12 reports that silencing of Nox1 abrogates the elevation in O 2 − production and inflammatory gene expression in human endothelial cells treated with high glucose, whereas the influence of Nox4 silencing is limited to H 2 O 2 . Another study shows Nox1, but not Nox2 or Nox4 expression, to be upregulated in response to high glucose in a microvascular endothelial cell line. 13 Further, gene silencing techniques reveal cellular events involved in neointima formation to be driven by Nox1 activation in cell lines of vascular smooth muscle cells, namely, phenotypic modulation and proliferation in response to cyclic stretch 14 and low-density lipoprotein. 15 This putative role of Nox1 in diabetes mellitus-induced atherosclerosis holds true in the intact animal, as demonstrated by the seminal article by Gray et al. In this study, genetic deletion of Nox1, but not Nox4, abolished atherosclerotic lesion development in aortae of ApoE −/− mice made diabetic by daily injections of streptozotocin. 12 Herein, we provide the first direct evidence linking Nox1 to the early microvascular changes that precede the development of hypertension and end-organ damage. Together, these findings generate an impetus to substantiate the value of targeted Nox1 inhibition in the prevention of macrovascular and microvascular complications in metabolic disease. The present study focused on the mesenteric artery, which represents a peripheral vascular bed that undergoes vasomotor changes underlying the resistance component of abnormal hemodynamic patterns in MetS. Reduced vasodilatory capacity is a highly documented finding in metabolic disease, which manifests during the subclinical stages in both atherosclerotic-resistant arteries, such as the mesenteric artery and atherosclerotic-prone arteries 22, 23 and is an independent predictor of cardiovascular death. 8 Three recent studies provide indirect evidence implicating Nox1 as a causative factor in the reduced vasodilatory responses exhibited by the db/db model. The first, published by Liang et al, 24 reports a reduction in Nox1 mRNA and protein levels to accompany improved endothelium-dependent dilatory responses in aortae of db/db mice with toll-like receptor 4 mutation. The authors of the second study also attributed impaired dilatory capacity to Nox-derived ROS on the grounds that endothelium-dependent and independent dilatory responses were restored along with decreases in ROS production and Nox1/2/4 expression in mesenteric arteries of db/db mice treated with atorvastatin. 25 Correlative changes in protein expression do not necessarily establish Nox1 as the primary agent in pathogenesis given the many sources of ROS and the lack of specificity and sufficient validation of currently available antibodies against Nox1. 26 The third study, published by our group, showed an improvement in endothelium-dependent dilation in db/db mice after in vitro treatment with GKT136901-a Nox1/4 inhibitor. 16 Direct evidence specifically linking Nox1 to microvascular dysfunction is provided by the present study with the finding that blunted endothelium-dependent and independent dilation in the mesenteric arteries of db/db mice are recovered with loss of Nox1 in the absence of changes in body composition or metabolism. Endothelial function was assessed by measuring responses to acetylcholine-an activator of eNOS. Although there was no difference in eNOS mRNA expression between groups, acute inhibition of eNOS with L-NAME had differential effects on acetylcholine responses, with no impact on db/db mice and a drastic blunting effect in double knockout animals. Furthermore, incubation of vessels with Tempol-a SOD mimetic-improved acetylcholine responses in obese mice with Nox1 intact but had no influence on lean and double knockout animals. Together, these results suggest that the beneficial effect of Nox1 deletion on endothelial function is, at least in part, because of a restoration of NO bioavailability via normalization of O 2 − production-the most well-characterized means by which ROS mediate vascular dysfunction. Reduced staining of dihydroethidium and nitrotyrosine immunoreactivity in double knockout animals lends further support to the conclusion that Nox1 deletion prevents excess O 2 − production and oxidative stress in MetS. Therefore, Nox1 is a principal source of ROS and mediator of NO-related endothelial dysfunction under conditions of metabolic compromise.
There are multiple mechanisms in addition to NO depletion by which Nox1-derived ROS may promote development of vascular dysfunction, including the modulation of redoxsensitive signaling pathways involved in vasomotor function and structural changes because of abnormal extracellular matrix turnover or cytoskeleton reorganization. One or more of these mechanisms may participate in the abnormal vascular smooth muscle cell (VSMC) behavior observed in db/db mice of the current study, evident by loss of myogenic regulation and impairment of vasodilatory responses to an NO donor. Nox1 is expressed in VSMC of microvessels; 16 therefore, improvement of VSMC function in mice lacking Nox1 suggests that the VSMC responses to adverse metabolic stimuli are predominately driven by local ROS generation via Nox1.
Myogenic responsiveness is an intrinsic property of VSMC that autoregulates organ perfusion amid fluctuations in upstream pressure. Heightened myogenic contraction in response to elevations in intraluminal pressure has been reported in hypertensive and diabetic patients 27 and in animal models of these disorders. [28] [29] [30] [31] However, with the persistence of hypertension or metabolic dysfunction, myogenic control is lost and with it, the ability to protect down-stream organs from excessive increases in perfusion pressure. Thus, impairment of myogenic responsiveness, as observed in db/db mice of the present study, contributes to the end-organ damage that accompanies complications of MetS. This transition from compensatory increases in myogenic tone to autoregulatory failure has been observed in the type 2 diabetic Goto-Kakizaki rat, in that exaggerated pressure-induced contraction precedes loss of myogenic responses with aging. [32] [33] [34] Impaired myogenic reactivity contributes to renal injury in the Dahl salt-sensitive rat, 35 whereas enhanced myogenic contractions and preserved renal function are found in the spontaneously hypertensive rat. 28 Similarly, in diabetic patients, loss of myogenic control is associated with the development of retinopathy. 36 Last, Schofield et al 27 reveals that when essential hypertension is compounded by type 2 diabetes mellitus, myogenic responsiveness weakens in small arteries harvested from subcutaneous fat. The present study is the first to identify Nox1-derived ROS as critical in mediating autoregulatory failure in the setting of severe metabolic disease.
Little investigation has been directed toward understanding the link between ROS and autoregulatory abnormalities in states of metabolic compromise. In one study, transgenic overexpression of SOD, SOD1, prevented the blunting of myogenic reactivity in cerebral vessels that resulted from high glucose exposure before ischemia-reperfusion injury. 37 Similarly, eliminating ROS with antioxidants restored myogenic responses in rats fed a high-sugar diet. 38 Still, less is known with respect to the distinct roles of the Nox isoforms. Herein, we present novel data showing that transgenic loss of Nox1 in db/db mice virtually normalizes myogenic regulation. To our knowledge, the only data providing insight into a potential mechanism by which Nox1 impairs myogenic tone is that published by Howit et al 39, 40 linking Nox enzymes to the modulation of calcium channel function after acute NO depletion. There are multiple other levels along the cascade of events orchestrating myogenic responses that may be affected by Nox1-derived ROS, the identification thereof is beyond the scope of this study. Nevertheless, our data reveal a causal role of Nox1 in the loss of myogenic regulation in metabolic disease.
It is possible that the profound impact of targeted Nox1 inhibition on microvascular function is, in part, attributable to a secondary effect on other enzymatic sources of ROS. Excess ROS by one source can trigger ROS release by another, thereby triggering a cycle of unfettered ROS accumulation. The Nox are increasingly viewed as drivers of this feed-forward cycle. Indeed, uncoupled eNOS is a significant source of vascular O 2 − and cause of NO depletion in the diabetic state, 41 and there exist data implicating Nox1 as a mediator of eNOS uncoupling under such conditions. Specifically, a study performed by Youn et al 42 demonstrates that eNOS uncoupling is reversed with genetic deletion of Nox1 or transfection of Nox1 siRNA, but preserved with loss of Nox2, in a model of type 1 diabetes mellitus. Further, mitochondrial enzymes release ROS as by-products of cellular respiration, but contribute to ROS overabundance in pathological states, such as diabetes mellitus. Mitochondriaderived ROS were reduced in endothelial cells after blocking of Nox activation via depletion of the P22 phox subunit, as shown by Doughan et al. 43 Data presented in the current article show that Nox1 deletion attenuates total oxidant load as measured by circulating levels of lipid peroxidation products, providing evidence that the detrimental effects of Nox1 are owing to its synergistic effects with other ROSproducing enzymes.
There are several caveats to the present study that should be noted. First, our model of obesity is the db/db mouse, chosen because it consistently produces metabolic dysfunction consequent to excess caloric intake and accompanying endothelial dysfunction, much like human obesity. It should be noted, however, that obesity manifests in different individuals for various reasons and risk factors such as elevated low-density lipoprotein cholesterol that are not mimicked in our model may impact application of these findings in other forms of obesity. Second, although we provide functional evidence suggesting that Nox1 contributes to both endothelial and VSMC dysfunction in the setting of metabolic disease, the global knockout approach does not reveal whether endothelial cells or smooth muscle cells are primarily affected or whether both are equally involved. The results of these experiments should provide a substantial basis for cell-specific deletion studies of NOX1 in obesity and other models of metabolic vascular disease.
In summary, this study provides novel data showing that selective deletion of Nox1 is sufficient to reduce oxidant load and restore vasomotor responses of mesenteric arteries in the face of severe metabolic compromise, thus, highlighting Nox1 as critical in mediating the injurious effects of adverse metabolic stimuli on the microvasculature. Loss of hemodynamic control consequent to microvascular dysfunction is an important antecedent to the end-organ damage underlying cardiovascular complications of MetS. Therefore, selective inhibition of Nox1 may be effective in preventing cardiovascular death in MetS, which remains a significant clinical challenge, despite current therapies effective in controlling blood glucose and lipid levels.
